STOCK TITAN

[Form 4] Arteris, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Arteris, Inc. director Joachim Kunkel reported receipt of 1,496 shares of common stock as fully vested restricted stock on 10/05/2025. The shares were issued as retainer fees elected in lieu of cash and the reporting person elected to defer receipt; the transaction price is reported as $0.00.

Following the transaction, the reporting person beneficially owns 67,818 shares. The Form 4 was signed by an attorney-in-fact on 10/06/2025 and indicates the filing is by one reporting person and that the reporting person is a director.

Arteris, Inc. direttore Joachim Kunkel ha comunicato di aver ricevuto 1,496 azioni ordinarie completamente maturate come azioni soggette a restrizioni il 10/05/2025. Le azioni sono state emesse come compensi di ritenuta eleggibili al posto del pagamento in contanti e la persona segnalante ha scelto di differire la ricezione; il prezzo della transazione è riportato come $0.00. A seguito della transazione, la persona segnalante detiene beneficiamente 67,818 azioni. Il Modulo 4 è stato firmato da un procuratore il 10/06/2025 e indica che la presentazione è fatta da una sola persona segnalante e che quest'ultima è un direttore.
El director de Arteris, Inc. Joachim Kunkel informó sobre la recepción de 1,496 acciones ordinarias como acciones restringidas totalmente vested el 10/05/2025. Las acciones fueron emitidas como honorarios de retención elegidos en lugar de efectivo y la persona reportante optó por diferir la recepción; el precio de la transacción se informa como $0.00. Después de la transacción, la persona reportante posee beneficiosamente 67,818 acciones. El Formulario 4 fue firmado por un apoderado el 10/06/2025 e indica que la presentación es por una única persona reportante y que la persona reportante es un director.
Arteris, Inc. 이사 Joachim Kunkel은 10/05/20251,496 주의 일반주를 완전히 귀속된 제한주로 수령했다고 보고했다. 주식은 현금 대신 유보 보수로 발행되었으며 보고자는 수령을 연기하기로 선택했다; 거래 가격은 $0.00로 보고된다. 거래 후 보고자는 실질적으로 67,818주를 보유한다. Form 4는 10/06/2025에 대리인에 의해 서명되었으며, 제출은 한 명의 보고자에 의해 이루어지며 보고자는 이사임을 나타낸다.
Le directeur Joachim Kunkel d'Arteris, Inc. a signalé avoir reçu 1,496 actions ordinaires entièrement acquises en tant qu'actions restreintes sur le 10/05/2025. Les actions ont été émises comme honoraires de retenue élus en lieu et place de l'argent et la personne signalante a choisi de différer la réception; le prix de la transaction est reporté comme $0.00. Suite à la transaction, la personne signalante détient bénéficiairement 67,818 actions. Le Formulaire 4 a été signé par un mandataire le 10/06/2025 et indique que le dépôt est effectué par une seule personne signalante et que cette personne est un directeur.
„Arteris, Inc.“ Direktor Joachim Kunkel meldete den Erhalt von 1,496 Stammaktien als vollständig vestierte Restricted Stock am 10/05/2025. Die Aktien wurden als Retainer-Gebühren in statt Bar ausgegeben, und die meldende Person wählte die Empfangsbewilligung; der Transaktionspreis wird als $0.00 angegeben. Nach der Transaktion besitzt die meldende Person vorteilhaft 67,818 Aktien. Das Formular 4 wurde von einem Bevollmächtigten am 10/06/2025 unterschrieben und gibt an, dass die Einreichung von einer meldenden Person erfolgt und dass die meldende Person ein Direktor ist.
مدير Arteris, Inc. جان كُونكل أبلغ عن استلام 1,496 من الأسهم العادية كإسناد أسهم مقيدة تماماً في 10/05/2025. تم إصدار الأسهم كتعويضات احتجاز تم اختيارها بدلاً من النقد وقررت الشخص المبلغة تأجيل الاستلام؛ يُذكر سعر الصفقة بأنه $0.00. بعد الصفقة، يمتلك الشخص المبلّغ فعلياً 67,818 سهمًا. تم توقيع النموذج 4 بواسطة وكيل في 10/06/2025 ويشير إلى أن الإيداع يتم من قِبل شخص واحد وأن الشخص المبلّغ هو مدير.
“Arteris, Inc.” 董事 Joachim Kunkel 于 10/05/2025 报告收到 1,496 股普通股,作为完全归属的限制性股票在 10/05/2025。这些股票作为留任费形式发行,以替代现金支付,且报告人选择推迟领取;交易价格显示为 $0.00。交易完成后,报告人实益拥有 67,818 股。 Form 4 由代理人于 10/06/2025 签署,表明归档由一名报告人进行,且报告人为 董事
Positive
  • None.
Negative
  • None.

Insights

Director accepted stock retainer; ownership modestly increased.

The director received 1,496 fully vested restricted shares as a retainer elected in lieu of cash, which increases his direct stake to 67,818 shares. Receiving compensation in equity aligns executive/director pay with shareholder outcomes and removes immediate cash outflow for the company.

This arrangement depends on the board’s compensation policy and share plan limits; the filing notes the reporting person elected to defer receipt, which can affect timing of ownership transfer and potential tax treatment. Monitor subsequent Form 4s for sales or additional grants within the next 12 months.

Arteris, Inc. direttore Joachim Kunkel ha comunicato di aver ricevuto 1,496 azioni ordinarie completamente maturate come azioni soggette a restrizioni il 10/05/2025. Le azioni sono state emesse come compensi di ritenuta eleggibili al posto del pagamento in contanti e la persona segnalante ha scelto di differire la ricezione; il prezzo della transazione è riportato come $0.00. A seguito della transazione, la persona segnalante detiene beneficiamente 67,818 azioni. Il Modulo 4 è stato firmato da un procuratore il 10/06/2025 e indica che la presentazione è fatta da una sola persona segnalante e che quest'ultima è un direttore.
El director de Arteris, Inc. Joachim Kunkel informó sobre la recepción de 1,496 acciones ordinarias como acciones restringidas totalmente vested el 10/05/2025. Las acciones fueron emitidas como honorarios de retención elegidos en lugar de efectivo y la persona reportante optó por diferir la recepción; el precio de la transacción se informa como $0.00. Después de la transacción, la persona reportante posee beneficiosamente 67,818 acciones. El Formulario 4 fue firmado por un apoderado el 10/06/2025 e indica que la presentación es por una única persona reportante y que la persona reportante es un director.
Arteris, Inc. 이사 Joachim Kunkel은 10/05/20251,496 주의 일반주를 완전히 귀속된 제한주로 수령했다고 보고했다. 주식은 현금 대신 유보 보수로 발행되었으며 보고자는 수령을 연기하기로 선택했다; 거래 가격은 $0.00로 보고된다. 거래 후 보고자는 실질적으로 67,818주를 보유한다. Form 4는 10/06/2025에 대리인에 의해 서명되었으며, 제출은 한 명의 보고자에 의해 이루어지며 보고자는 이사임을 나타낸다.
Le directeur Joachim Kunkel d'Arteris, Inc. a signalé avoir reçu 1,496 actions ordinaires entièrement acquises en tant qu'actions restreintes sur le 10/05/2025. Les actions ont été émises comme honoraires de retenue élus en lieu et place de l'argent et la personne signalante a choisi de différer la réception; le prix de la transaction est reporté comme $0.00. Suite à la transaction, la personne signalante détient bénéficiairement 67,818 actions. Le Formulaire 4 a été signé par un mandataire le 10/06/2025 et indique que le dépôt est effectué par une seule personne signalante et que cette personne est un directeur.
„Arteris, Inc.“ Direktor Joachim Kunkel meldete den Erhalt von 1,496 Stammaktien als vollständig vestierte Restricted Stock am 10/05/2025. Die Aktien wurden als Retainer-Gebühren in statt Bar ausgegeben, und die meldende Person wählte die Empfangsbewilligung; der Transaktionspreis wird als $0.00 angegeben. Nach der Transaktion besitzt die meldende Person vorteilhaft 67,818 Aktien. Das Formular 4 wurde von einem Bevollmächtigten am 10/06/2025 unterschrieben und gibt an, dass die Einreichung von einer meldenden Person erfolgt und dass die meldende Person ein Direktor ist.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kunkel Joachim

(Last) (First) (Middle)
C/O ARTERIS, INC.
900 E. HAMILTON AVE., SUITE 300

(Street)
CAMPBELL CA 95008

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arteris, Inc. [ AIP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/05/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/05/2025 A 1,496(1)(2) A $0.00 67,818 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Fully vested restricted stock. The restricted stock represents retainer fees that the Reporting Person elected to receive in the form of shares of common stock in lieu of cash.
2. The Reporting Person elected to defer the receipt of shares.
Remarks:
/s/ Paul Alpern as Attorney-in-fact for Joachim Kunkel 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Arteris, Inc.

NASDAQ:AIP

AIP Rankings

AIP Latest News

AIP Latest SEC Filings

AIP Stock Data

579.19M
29.79M
30.11%
47.91%
3.85%
Semiconductors
Semiconductors & Related Devices
Link
United States
CAMPBELL